Startups
Life sciences investors are being anything but shy as the end of 2021 draws near. Here are a few companies that are still seeing cash come in the door as December gets underway.
Tune claims TEMPO can rapidly target and adjust the epigenomic machinery, controlling gene expression and dictating how the DNA will be molded.
The radiopharmaceuticals being developed by Curie are composed of rationally designed conjugates in contrast to delicately chosen biological targets.
The precision medicine company is developing mutant selective and isoform-specific drugs in non-conventional ways for well-known targets in the oncology and autoimmune spaces.
Plenty to be thankful for this week for these biopharma companies, especially with the influx of cash.
Vaccibody has changed its name to Nykode Therapeutics. “Nykode” means “new code,” which plays on the potential of the company to generate novel codes and innovative patient therapies.
Avilar Therapeutics officially joined the game with $60 million in seed financing from RA Capital Management.
Chroma Medicine debuted Wednesday morning with $125 million in seed and Series A funding.
Eric Ostertag, CEO of Poseida Therapeutics, believes the future of CAR-T programs is with allogeneic approaches and not autologous.
Investors are lighting up the season already for these biotechs, now flush with cash to spend. Here’s who snagged funding this week.
PRESS RELEASES